Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
cancer
12
×
life sciences
national blog main
san francisco blog main
boston blog main
boston top stories
national top stories
san francisco top stories
indiana blog main
indiana top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
eli lilly
startups
investing
cancer immunotherapy
fda
novartis
pfizer
roche
abbvie
alzheimer's disease
What
drug
12
×
roundup
bio
cancer
companies
new
biotech
fda
medicines
research
alzheimer’s
annual
approval
attention
ipo
latest
lead
market
nash
news
patients
plan
price
prices
targets
today
week
acquisitions
address
advance
advantages
ahead
ambien
american
approved
approves
asco
assessed
attendees
bar
Language
unset
Current search:
biotech
×
cancer
×
drug
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs